Showing results (1-10 of 422) with videos related to
Sort By:
Pageof 43
Current Opinion in Nephrology and Hypertension|September 28, 2023
Combination therapy with kidney protective therapies: optimizing the benefits?Sradha Kotwal, Evan Perkovic, Vlado PerkovicExpert Review of Clinical Pharmacology|August 1, 2022
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuriaNasir Shah, Vlado Perkovic, Sradha KotwalCirculation. Cardiovascular Quality and Outcomes|November 1, 2012
Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysisSradha Kotwal, Min Jun, David Sullivan, et al.F1000Research|December 14, 2018
New hypoglycemic agents and the kidney: what do the major trials tell us?Brendan Smyth, Vlado PerkovicNephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 19, 2026
Sex disparities in receiving evidence-based medications in patients with CKDRui Du, Hannah Wallace, Jeffrey T Ha, et al.Internal Medicine Journal|April 11, 2025
Glomerular disease registry and biobank: design and baseline resultsAndrew Jeyaruban, Bhadran Bose, Vincent W Lee, et al.BMJ Open|September 4, 2025
Quality of care for people with chronic kidney disease: a systematic review and meta-analysisDaniel Bekele Ketema, Hannah Wallace, Workagegnehu Hailu, et al.Diabetes, Obesity & Metabolism|January 9, 2025
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trialAmanda Siriwardana, Luke Buizen, Min Jun, et al.Diabetes & Vascular Disease Research|March 3, 2012
Effects of SGLT2 inhibitors on cardiovascular outcomesCeline Foote, Vlado Perkovic, Bruce NealDiabetes, Obesity & Metabolism|May 29, 2024
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trialNavdeep Tangri, Thomas W Ferguson, Ryan J Bamforth, et al.Pageof 43